|
|
|
The IMF is making news all year round.
|
|
|
|
|
Cancer Patient Advocate Leaders from 11 Countries Gather June 13th
Advocate from Turkey Says Patients Are Desperate for Mutual Support
|
|
|
|
|
--CHMP Recommendation for Pomalidomide Is Good News for Myeloma Patients in Europe--
--Pomalidomide (POMALYST® in the U.S.) Is an Oral Therapy FDA Approved in the United States for Patients Who Have Had Multiple Prior Treatments--
--The IMF Looks for Other Anti-Myeloma Agents Including KYPROLIS® (Carfilzomib) to Follow--
|
|
|
|
In Recognition of Significant Contributions to Myeloma Research and Patient Care
|
|
|
|
The federal Cancer Drug Coverage Parity Act will dramatically improve the lives of cancer patients. Patients who previously could not afford these treatments will be able to access their life-saving effects. It will also make cancer treatments more practical for patients living in rural and underserved areas by reducing the need to drive long distances for a nurse or doctor to administer treatment. |
|
|
|
An entirely new approach to
monitoring treatment efficacy to achieve a cure. |
|
|
|
Newly Approved POMALYST® (Pomalidomide) Is an Oral Therapy with Demonstrated Overall Survival Benefit in Patients Who Have Had Multiple Prior Treatments |
|
print
back to top